| 产品名称： | Vaccinia virus ts mutant |
|---|---|
| 商品货号： | TS213292 |
| Classification： | Poxviridae, Orthopoxvirus |
| Deposited As： | Vaccinia virus, Orthopoxvirus |
| Agent： | Vaccinia virus ts mutant |
| Strain： | IHD-W Dts22 |
| Applications： | The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location G2, a positive transcription elongation factor. |
| Biosafety Level： | 2 BSL 2Vaccination recommended for lab staff manipulating vaccinia, monkeypox, or cowpox viruses. ref
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | This conditional lethal mutant, originally designated plaque isolate no. 3145, was isolated from the IHD-W strain of Vaccinia by S. Dales. The IHD-W strain was derived from an IHD-J strain of Vaccinia |
| Product Format： | frozen |
| Storage Conditions： | -70°C or colder |
| Comments： | Not described in the original publication, but presumed to have been selected after mutagenesis with nitrosoguanidine. The non-permissive incubation temperature is 39.5 C. This mutant was not assigned to a Dales EM category. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location G2, a positive transcription elongation factor. |
| Effect on Host： | Cytopathic effects (CPE): enlargement, plaques with rounding and eventual sloughing CPE: enlargement, plaques with rounding and eventual sloughing |
| Growth Medium： | ATCC® Medium 30-2003: Eagles Minimum Essential Medium (EMEM) Fetal Bovine Serum |
| Recommended Host： | Production Host: BSC-40 (ATCC CRL-2761) Recommended Host: BSC-40 (ATCC CRL-2761) Alternate Host(s): MRC-5, BS-C-1, HeLa, LLC-MK2 |
| Growth Conditions： | 1-3 days at 31 C with 5% CO2 |
| Name of Depositor： | S Dales & R Condit |
| References： | Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807 Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570 Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Vaccinia virus ts mutant |
|---|---|
| 商品货号： | TS213292 |
| Classification： | Poxviridae, Orthopoxvirus |
| Deposited As： | Vaccinia virus, Orthopoxvirus |
| Agent： | Vaccinia virus ts mutant |
| Strain： | IHD-W Dts22 |
| Applications： | The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location G2, a positive transcription elongation factor. |
| Biosafety Level： | 2 BSL 2Vaccination recommended for lab staff manipulating vaccinia, monkeypox, or cowpox viruses. ref
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | This conditional lethal mutant, originally designated plaque isolate no. 3145, was isolated from the IHD-W strain of Vaccinia by S. Dales. The IHD-W strain was derived from an IHD-J strain of Vaccinia |
| Product Format： | frozen |
| Storage Conditions： | -70°C or colder |
| Comments： | Not described in the original publication, but presumed to have been selected after mutagenesis with nitrosoguanidine. The non-permissive incubation temperature is 39.5 C. This mutant was not assigned to a Dales EM category. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location G2, a positive transcription elongation factor. |
| Effect on Host： | Cytopathic effects (CPE): enlargement, plaques with rounding and eventual sloughing CPE: enlargement, plaques with rounding and eventual sloughing |
| Growth Medium： | ATCC® Medium 30-2003: Eagles Minimum Essential Medium (EMEM) Fetal Bovine Serum |
| Recommended Host： | Production Host: BSC-40 (ATCC CRL-2761) Recommended Host: BSC-40 (ATCC CRL-2761) Alternate Host(s): MRC-5, BS-C-1, HeLa, LLC-MK2 |
| Growth Conditions： | 1-3 days at 31 C with 5% CO2 |
| Name of Depositor： | S Dales & R Condit |
| References： | Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807 Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570 Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
